Daily Newsletter

14 August 2023

Daily Newsletter

14 August 2023

ReWalk Robotics concludes acquisition of AlterG

Charles Remsberg, who formerly served as CEO of AlterG, has taken on the role of chief sales officer at ReWalk.

RanjithKumar Dharma August 14 2023

Medical device company ReWalk Robotics concluded the acquisition of US-based AlterG last week for a purchase price of around $19m in cash.

The acquisition agreement outlines the option for ReWalk to make two potential earnout payments.

These payments will be based on a percentage of the year-over-year revenue growth of AlterG during each of the two consecutive trailing 12-month periods following the completion of the transaction.

The merged company is expected to provide expanded access for patients to new rehabilitation technologies used in clinics and at home.

Established in 2005, AlterG supplies Anti-Gravity systems designed for physical and neurological rehabilitation applications.

Leveraging Differential Air Pressure technology, the Anti-Gravity system reduces the effects of gravity, allowing individuals to move in new ways with finely calibrated support and reduced discomfort.

AlterG systems are present in over 4,000 facilities globally, aiding millions in attaining its goals safely, leading to improved mobility results.

Following the completion of the transaction, Charles Remsberg, who formerly served as the CEO of AlterG, has taken on the role of chief sales officer at ReWalk.

ReWalk CEO Larry Jasinski said: “We are exceedingly pleased to have now formally combined the unique and complementary strengths of our two organisations.

“We now look forward to applying our respective competencies and leveraging our synergies to expand clinician and patient access to the innovative technologies within our combined portfolio.”

Established in 2001, ReWalk develops and markets advanced technologies that facilitate mobility and wellness in rehabilitation and daily life for people with neurological conditions.

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close